HSBC Holdings
AKRO

HSBC Holdings’s Akero Therapeutics AKRO Stock Holding History

HSBC Holdings’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-8,647
Closed -$343K – 3012
2025
Q1 		$343K Buy
8,647
+761
+10% +$32.3K ﹤0.01% 2295
2024
Q4 		$220K Buy
7,886
+621
+9% +$18.8K ﹤0.01% 2668
2024
Q3 		$208K Buy
+7,265
New +$189K ﹤0.01% 2588
2022
Q3 		– Sell
-13,064
Closed -$124K – 2903
2022
Q2 		$124K Buy
+13,064
New +$136K ﹤0.01% 3000
2019
Q4 		– Sell
-27,014
Closed -$615K – 3019
2019
Q3 		$615K Buy
+27,014
New +$629K ﹤0.01% 2215

Other funds holding AKRO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HSBC Holdings's AKRO Position: Q2 2025 in Review

HSBC Holdings sold out of Akero Therapeutics (AKRO) in Q2 2025, closing a stake of 8,647 shares — an estimated $343K sold.

HSBC Holdings first reported a position in AKRO in Q3 2019 and held it in 5 quarters. The position peaked at $615K in Q3 2019. 257 funds tracked by Wall St. Rank hold AKRO as of Q2 2025.

  • HSBC Holdings reported no remaining Akero Therapeutics position as of Q2 2025 after selling out during the quarter.
  • HSBC Holdings sold 8,647 Akero Therapeutics shares in Q2 2025, an estimated $343K.
  • HSBC Holdings first reported a position in Akero Therapeutics in Q3 2019 and held it in 5 quarters.
  • HSBC Holdings's Akero Therapeutics position peaked at $615K in Q3 2019.
  • 257 funds tracked by Wall St. Rank held Akero Therapeutics as of Q2 2025.

Based on HSBC Holdings's 13F filing for Q2 2025, filed 13 Aug 2025.